Melanotan II
(Synonyms: 美拉诺坦 (MT)-II) 目录号 : GC16276A melanocortin receptor agonist
Cas No.:121062-08-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Rats: To investigate the inducer activity on erection, melanotan (MT)-II or vehicle (saline) is acutely injected i.v., i.t. or within the PVN after a 5 min baseline recording period is obtained. ICP and MAP are then recorded for a 60 min period after saline or melanotan (MT)-II delivery. I.v. injections (three doses; 0.1, 0.3, and 1 mg/kg in saline) are performed with a catheter inserted in the jugular vein[2]. Mice: Melanotan (MT)-II (0.1 and 0.2 nM) or vehicle (artificial cerebrospinal fluid) is administered. SPA is recorded continuously every 5 min. Food intake measurements are taken 6 and 24 h postinjection. Body weight is measured every 24 h. Chow and water are available ad libitum. A 48-h interval occurrs between drug treatments[5]. |
References: [1]. Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164-72. |
Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning.
Melanotan (MT)-II is a potent non-selective melanocortin receptor agonist with high affinity for MC1, MC3, MC4, and MC5 receptor subtypes which are involved in the regulation of a number of physiological systems such as the pigmentary system, energy homoeostasis, sexual functioning, the immune system, inflammation, and the cardiovascular system[1].
Melanotan (MT)-II exerts a dose-dependent inducer activity on erection by eliciting erectile events and shortening latency of the first erectile event to occur. Erectile responses elicited by cavernous nerve stimulation are increased after i.v. melanotan (MT)-II (1 mg/kg), thereby exerting facilitator effect on erection[2]. Melanotan (MT)-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Melanotan (MT)-II significantly enhances the recovery of sensory function following a crush lesion of the sciatic nerve in the rat at a dose of 20 μg/kg per 48 h, s.c., but not at a dose of 2 or 50 μg/kg[3]. Melanotan (MT)-II is a potent initiator of penile erection in men with erectile dysfunction[4]. Melanotan (MT)-II reduces food intake and body weight and invokes thermogenic responses in a mouse model[5].
References:
[1]. Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164-72.
[2]. Giuliano F, et al. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301.
[3]. Ter Laak MP, et al. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003 Feb 21;462(1-3):179-83.
[4]. Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9.
[5]. De Jonghe BC, et al. Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency. Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E644-51.
Cas No. | 121062-08-6 | SDF | |
别名 | 美拉诺坦 (MT)-II | ||
化学名 | (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-((diaminomethylene)amino)propyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide | ||
Canonical SMILES | O=C([C@H](CCC/N=C(N)\N)NC([C@@H](CC1=CC=CC=C1)NC([C@H](CC2=CN=CN2)NC([C@H](C3)NC([C@H](CCCC)NC(C)=O)=O)=O)=O)=O)N[C@H](C(N[C@H](C(N)=O)CCCCNC3=O)=O)CC4=CNC5=CC=CC=C45 | ||
分子式 | C50H69N15O9 | 分子量 | 1024.19 |
溶解度 | Soluble to 1 mg/ml in sterile water | 储存条件 | Desiccate at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.9764 mL | 4.8819 mL | 9.7638 mL |
5 mM | 0.1953 mL | 0.9764 mL | 1.9528 mL |
10 mM | 0.0976 mL | 0.4882 mL | 0.9764 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。